Unlock the true power of particles
Particle Works is proud to be the only company in the market that provides a truly end-to-end solution for developing and manufacturing lipid nanoparticles.
Underpinned by microfluidics and automation, all our systems utilize the same microfluidic process technology, pumps, and reusable glass microfluidic chips. Our approach ensures consistent, flexible and efficient workflows, from formulation screening through protocol optimization to GMP scale-up manufacturing and commercialization; ideal for LNP encapsulation in vaccines, drugs and gene therapy.
Our expertise and cutting-edge technology enable us to deliver a seamless and streamlined solution that meets the needs of our customers, driving innovation in the field of nanomedicine. Whether you are a researcher, scientist, or biotech company, we are committed to providing you with the highest quality, cost-effective and sustainable end-to-end solutions that help you achieve your research goals.
Born from Dolomite Microfluidics, with 20 years experience in particle technology, and a strong heritage of microfluidics, engineering and nanoparticle expertise, our range of platforms allow you to transfer between discovery, through development to manufacturing using the same process technology.
We have been at the forefront of this rapidly changing science, listening and adapting as our customers’ needs have evolved. We pave the way to particle perfection, helping our customers produce nanoparticles with unrivalled precision, quality, consistency and control, while reducing your development time and cost. Our product is your process.
Nanoparticles and nanoscale drug delivery systems (for materials such as small molecules, genetic material and other APIs) have become a significant part of the medical industry’s product research and development focus and the demand for nanoparticle-based medicines and therapies has exploded in recent years. The COVID-19 pandemic catapulted mRNA-based therapeutics into the forefront of life science, realizing the benefits of collaborative global efforts for unprecedented drug development.
There is a clear need for automated, effective and efficient production of LNPs for screening, optimization and manufacturing. We recognise that rapid product development requires acceleration and parallel task execution, and scalability and automation are key to address both requirements. Microfluidics is central to achieving scalability and quality issues that traditional methods cannot address.
Microfluidics controls particle size, achieves excellent monodispersity and encapsulation efficiency. Particle integrity is preserved and damage caused by mechanical forces is avoided. Particle Works has developed 4 core platforms to meet the various demands of the drug discovery journey, and using our reusable microfluidics chips ensures that our process technology is scalable across the whole of your drug development pipeline.
Using the same microfluidic chips and pumping technology at every stage of nanoparticle development ensures your formulations are transferrable and scalable right through from discovery, through development to scale-up and manufacturing.
We are on a journey together. From our game-changing screening platform ALiS – the first to bring automation and high-throughput screening to the marketplace; to the ANP System – a unique, comprehensive and flexible single system for both process optimization and continuous production; to Pilot – our scale-up system; our innovative, pioneering technologies offer the complete solution for our customers’ drug development pipeline.
A NEW game-changing formulation screening platform utilizing 96 well plates – the first to bring automation and high-throughput screening to the marketplace.
The Automated Library Synthesis (ALiS) System enables automation and high-throughput screening of LNP formulations and mRNA candidates in early-stage development. The platform delivers excellent monodispersity and encapsulation efficiency, enabling upto 96 experiments within 6 hours.
Experience complete process development in a single solution. A unique, comprehensive and flexible system for both process optimization and continuous production.
The Automated Nanoparticle (ANP) System enables automation of process development and initial production of larger samples of LNPs with a select number of promising formulations, tailored to the user’s individual needs for flexible multi-sample and multi-protocol capability.
ANP Pilot is the version of the ANP System that will be suitable for GMP environments. Perfect for users conducting final process development in a manufacturing environment, and for initial manufacture for clinical trials/low volume applications. Allowing continuous sample manufacturing, with a 57 liters throughput in 24h (15 g of LNPs, 1.5M Vaccine Doses), it has a direct translation from discovery to development and is scalable by running systems in parallel.
Our highest throughput platform, Titan, is the final step in your particle production journey, making high volume manufacture in GMP facilities a breeze. Allowing continuous manufacturing of 1,440 l in 24h (~400 g of LNPs, 40M Vaccine Doses), its modular structure enables process flexibility and it is scalable by running systems in parallel.
How our platforms can revolutionize your work
A new era of nanoparticle synthesis platforms
See our platforms in action
Would you like to see how our technology can help you with your drug development pipeline?
We would love to show you in person. Simply click on the button below to arrange a demonstration with one of our scientists and we will be in touch very soon!
Get inspired by people like you
Head of Delivery, Earli Inc.
Our goals are best addressed by a high-throughput engineering approach, enabling us to generate and test hundreds of LNP formulations at small scale, then rapidly advancing the best candidates to larger scale for in vivo testing. Particle Works’ formulation platforms – the ALiS and ANP Systems – provide a strong solution for our needs, allowing us to maintain a precisely controlled formulation process across multiple scales to support our discovery and development efforts.
Managing Director, NanoVation Therapeutics UK
We are very excited to partner with Particle Works and to use its ALiS platform in our LNP research. There is nothing on the market quite like it, and we believe it will be a game changer for the high-throughput screening of our formulations. ALiS’ ability to automate the preparation of nanoparticle formulations is unique, and we are excited to see the impact it will have on our work.
Dr Julia Rashba-Step
VP of R&D and Alliance Management, Phosphorex
The ANP System offers the best solution for nanoparticle formulation and process optimization providing robust, reproducible results and enabling us to deliver complex projects. We have complete faith in Particle Works’ capabilities.
Mologic, Centre for Advanced Rapid Diagnostics
Seeing is believing! Let us prove it.
Are you struggling to imagine what is achievable for your materials on our platforms? Do you want a clearer and more representative indication of how your experiments can be run on our platforms to get the best results? Whether you’ve tried microfluidics before or want to move from a batch to a flow protocol, our proof of principle studies will provide peace of mind and de-risk your purchase. We collaborate closely with you when offering this premium service, quickly testing your materials on our site.
Be part of our journey by exploring particles at events
28th June 2023: 14:00 GMT | 09:00 EDT
Unlocking cost-efficiency and versatility: Executing workflows for automated process optimization and scale-up production of pre-clinical LNPs with advanced microfluidics